Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer

Part of paid clinical trials in New York, New York.

Sponsor
Peter Kozuch
Study ID
NCT00459901
Phase
PHASE2
Status
Terminated

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer. Time to tumor progression, objective response rate, time to confirmed response rate, duration of confirmed response rate, time to treatment failure, and CEA response will be assessed.

Key Dates

First listed
Apr 13, 2007
Start date
Jun 30, 2004
Status verified
Apr 2015
Primary completion
Jun 30, 2005
Completion
Jun 30, 2005

Study Design

Enrollment
13 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer [ Time Frame: Time to tumor progression, time to confirmed response rate, time to treatment failure, . ]

Locations (1)

FacilityCityStateZIPSite coordinators
Beth Israel Medical CenterNew YorkNew York10003-

Find similar trials in New York, NY

By research site
Beth Israel Medical Center· New York, NY

Related Studies